A 7-year-old boy with Attention-Deficit/Hyperactivity Disorder (ADHD) presents with inattention, hyperactivity, and impulsivity affecting school performance. He has no cardiac history, normal blood pressure, and normal baseline ECG. What is the drug of choice for first-line pharmacological management?

Explanation

## First-Line Pharmacotherapy for ADHD **Key Point:** Methylphenidate is the first-line stimulant medication for ADHD in children, with the strongest evidence base and most rapid onset of action. ### Mechanism of Action Methylphenidate is a sympathomimetic amine that blocks the reuptake of dopamine and norepinephrine at the presynaptic terminal, increasing their availability in the prefrontal cortex and striatum — regions critical for attention, impulse control, and executive function. ### Efficacy & Evidence - **Response rate:** 70–80% of children with ADHD show clinically significant improvement - **Onset:** 30–60 minutes (immediate-release); 1–2 hours (extended-release) - **Duration:** 4–6 hours (IR); 8–12 hours (ER/XR formulations) - **Gold standard:** Most extensively studied and recommended by major guidelines (AAP, NICE, Indian Academy of Pediatrics) ### Dosing in Children - **Starting dose:** 5 mg once or twice daily - **Titration:** Increase by 5–10 mg weekly based on response and tolerability - **Typical range:** 10–60 mg/day in divided doses (IR) or single daily dose (ER) ### Pre-Treatment Screening - **Baseline assessment:** Blood pressure, heart rate, ECG (if cardiac risk factors present) - **Contraindications:** Uncontrolled hypertension, structural cardiac abnormalities, recent MI, arrhythmias, hyperthyroidism - **Monitoring:** Height, weight, appetite, sleep, mood, tics (every 3–6 months) **High-Yield:** Stimulants (methylphenidate and amphetamines) remain the most effective and fastest-acting class for ADHD in children and are preferred over non-stimulants as first-line agents. **Clinical Pearl:** In India, methylphenidate is available as immediate-release (5, 10 mg tablets) and extended-release formulations (10, 20, 30 mg). Extended-release variants (Concerta, Ritalin LA) are preferred for school-age children to improve compliance and reduce stigma of midday dosing. ### Comparison with Other Options | Drug Class | Onset | Efficacy | First-Line? | Notes | |---|---|---|---|---| | **Methylphenidate (Stimulant)** | 30–60 min | 70–80% | **Yes** | Fastest onset; most evidence | | Amphetamine (Stimulant) | 30–60 min | 70–80% | Yes, alternative | Similar efficacy; more abuse potential | | Atomoxetine (SNRI) | 2–4 weeks | 60–70% | No | Non-stimulant; slower onset; used if stimulants contraindicated | | Guanfacine (α2-agonist) | 1–2 weeks | 50–60% | No | Second-line; better for hyperactivity/impulsivity; lower efficacy | | Clonidine (α2-agonist) | 1–2 weeks | 50–60% | No | Second-line; sedation common; rarely used monotherapy | **Warning:** Do NOT confuse stimulant efficacy with abuse potential — therapeutic use in children does NOT increase risk of substance abuse; in fact, untreated ADHD is a risk factor for later substance use disorder.